塞斯特林-1可以减轻放射性轴性脊柱关节炎的心血管风险吗?
Selman Parlak1, Ahmet Taha Sahin2, Ahmet Lütfü Sertdemir3
1Department of Rheumatology, Beyhekim Training and Research Hospital, Konya, Türkiye.
Archives of rheumatology
|August 4, 2025
概括
放射性轴性脊髓关节炎 (r-axSpA) 患者的塞斯特林-1水平较低,与心血管风险增加和心脏功能受损有关. 降低塞斯特林-1可能会在r-axSpA患者中恶化炎症和氧化应激.
科学领域:
- 风湿病学和心脏病学
- 生物化学和分子生物学
背景情况:
- 放射性轴性脊椎关节炎 (r-axSpA) 是一种慢性炎症状况,与心血管 (CV) 风险升高有关.
- 在r-axSpA中持续的炎症有助于增加心血管风险.
- 塞斯特林-1是一种具有抗氧化和抗炎作用的蛋白质,对心血管保护至关重要.
研究的目的:
- 调查r-axSpA患者中Sestrin-1水平和心血管标志物之间的关联.
- 评估心声回声检测结果及其与r-axSpA.中的Sestrin-1的关系.
- 探索Sestrin-1在r-axSpA心血管并发症中的作用.
主要方法:
- 一项受控研究涉及48名r-axSpA患者和48名健康对照.
- 使用ELISA测量Sestrin-1水平,并通过超声波评估动脉内膜介质厚度 (CIMT).
- 收集人口统计,生化 (包括CRP和ESR) 和心声回声数据.
主要成果:
- 与对照组相比,r-axSpA患者的Sestrin-1水平显著降低 (P=.003).
- 塞斯特林-1水平与C反应蛋白 (CRP) 和红细胞沉率 (ESR) 有负相关.
- r-axSpA患者表现出增加的CIMT,减少右心室缩运动 (RVSM) 和下三环状平面缩外流 (TAPSE).
结论:
- r-axSpA患者出现Sestrin-1水平降低和亚临床心血管变化,包括增加CIMT和右心室功能受损.
- 降低的Sestrin-1可能会导致氧化应激和炎症的增加,加剧r-axSpA中的心血管风险.
- 需要进一步的研究来评估Sestrin-1作为r-axSpA.CV并发症生物标志物的潜力.
相关概念视频
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Rheumatic Heart Disease III: Medical Management
32
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
32
Rheumatic Heart Disease I: Introduction
40
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
40
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
58
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
58
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
119
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
119
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K


